We are live on ! Find out more
ABBV icon

AbbVie

2,063 hedge funds and large institutions have $96.3B invested in AbbVie in 2018 Q4 according to their latest regulatory filings, with 223 funds opening new positions, 681 increasing their positions, 895 reducing their positions, and 100 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more first-time investments, than exits

New positions opened: 223 | Existing positions closed: 100

44% more funds holding in top 10

Funds holding in top 10: 103148 (+45)

5% more funds holding

Funds holding: 1,9562,063 (+107)

0.93% less ownership

Funds ownership: 70.5%69.56% (-0.93%)

5% less capital invested

Capital invested by funds: $101B → $96.3B (-$4.78B)

6% less call options, than puts

Call options by funds: $1.13B | Put options by funds: $1.2B

24% less repeat investments, than reductions

Existing positions increased: 681 | Existing positions reduced: 895

Holders
2,063
Holders Change
+107
Holders Change %
+5.47%
% of All Funds
45.79%
Holding in Top 10
148
Holding in Top 10 Change
+45
Holding in Top 10 Change %
+43.69%
% of All Funds
3.29%
New
223
Increased
681
Reduced
895
Closed
100
Calls
$1.13B
Puts
$1.2B
Net Calls
-$74.7M
Net Calls Change
+$325M

ABBV Hedge Fund Activity: Q4 2018 in Review

2,063 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2018, worth a combined $96.3B — down 4.7% from $101B a quarter earlier.

Buyers outnumbered sellers: 223 funds opened new ABBV positions and 100 closed out — a net gain of 123 holders — while 681 added to existing stakes and 895 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $366M. The largest seller was Capital World Investors, cutting an estimated $531M.

  • 2,063 institutional investors held AbbVie (ABBV) as of Q4 2018, up from 1,956 in Q3 2018.
  • Funds reported $96.3B of AbbVie stock for Q4 2018, down 4.7% quarter-over-quarter.
  • 223 funds opened new AbbVie positions in Q4 2018 and 100 closed out, a net change of +123 holders.
  • The largest AbbVie buyer in Q4 2018 was Janus Henderson Group, an estimated $366M added.
  • The largest AbbVie seller in Q4 2018 was Capital World Investors, an estimated $531M sold.

Based on aggregated 13F filings for Q4 2018.